Bucindolol: A Pharmacogenomic Perspective on its Use in Chronic Heart Failure
Bucindolol is a non-selective β-adrenergic receptor blocker with α-1 blocker properties and mild intrinsic sympatholytic activity. The Beta-Blocker Evaluation of Survival Trial (BEST), which is the largest clinical trial of bucindolol in patients with heart failure, was terminated prematurely and fa...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2011-01-01
|
| Series: | Clinical Medicine Insights: Cardiology |
| Online Access: | https://doi.org/10.4137/CMC.S4309 |